CoChat

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis

Abstract

Background Aspirin and statins are both effective for primary prevention of coronary heart disease (CHD), but their combined use has not been well studied. Objective To perform a cost-utility analysis of the effects of aspirin therapy, statin therapy, combination therapy with both drugs, and no pharmacotherapy for the primary prevention of CHD events in men. Design Markov model. Data sources Published literature. Target population Middle-aged men without a history of cardiovascular disease at 6 levels of 10-year risk for CHD (2.5%, 5%, 7.5%, 10%, 15%, and 25%). Time horizon Lifetime. Perspective Third-party payer. Interventions Low-dose aspirin, a statin, both drugs as combination therapy, or no therapy. Outcome measure Cost per quality-adjusted life-year gained. Results of base-case analysis For 45-year-old men who do not smoke, are not hypertensive, and have a 10-year risk for CHD of 7.5%, aspirin was more effective and less costly than no treatment. The addition of a statin to aspirin therapy produced an incremental cost-utility ratio of 56,200 dollars per quality-adjusted life-year gained compared with aspirin alone. Results of sensitivity analysis Excess risk for hemorrhagic stroke and gastrointestinal bleeding with aspirin, risk for CHD, the cost of statins, and the disutility of taking medication had important effects on the cost-utility ratios. Limitations Several input parameters, particularly adverse event rates and utility values, are supported by limited empirical…

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-144-5-200603070-00007

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 50 references

Research works printed but not linked: 6

  1. Murphy M, 2002, Clin Evid, 91
  2. Minino AM, 2001, Natl Vital Stat Rep, 49, 1
  3. Sudlow C, 2001, Practitioner, 245, 859
  4. Chen Q, 2000, Inquiry, 37, 359
  5. Troche CJ, 1998, Eur Heart J, 19, C59
  6. 10.1001/jama.285.19.2486 · DOI · Paper page

Cited by

See all 204

Metadata

Authors
Pignone, M., Earnshaw, S., Tice, J. A., & Pletcher, M. J.
Affiliations
University of North Carolina at Chapel Hill (US)
Venue
Annals of Internal Medicine
Published
2006-03-07
Volume
144
Issue
5
Pages
326-336
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2010518325
Cited by
204
References
50
Citations by year
2026: 2 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 3 · 2021: 6 · 2020: 5 · 2019: 9 · 2018: 6 · 2017: 10 · 2016: 7 · 2015: 16 · 2014: 14 · 2013: 13 · 2012: 10
FWCI
17.34
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • UCLA - Biblioteca de Ciencias de la Salud (submittedVersion)
Funders
Centers for Disease Control and Prevention (1p30cd000138-01)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
aspirin, statins, combination therapy, primary prevention, coronary artery disease, cost-utility analysis, middle-aged men, 10-year cardiovascular risk, quality-adjusted life years, hemorrhagic stroke, gastrointestinal bleeding
MeSH terms
Aspirin, Computer Simulation, Coronary Disease, Cost-Benefit Analysis, Drug Therapy, Combination, Fibrinolytic Agents, Gastrointestinal Hemorrhage, Humans, Male, Markov Chains, Middle Aged, Primary Prevention, Risk Factors, Sensitivity and Specificity, Drug Costs, Quality-Adjusted Life Years, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis. https://app.cochat.ai/papers/10.7326/0003-4819-144-5-200603070-00007
The paper
Pignone, M., Earnshaw, S., Tice, J. A., & Pletcher, M. J. (2006). Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-144-5-200603070-00007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.